Loading...
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1
Author(s)
Ludwig, Seth D.
Tan, Jiacheng
Kureshi, Rakeeb
Mishra, Akhilesh
Kaeo, Kyle J.
Zhu, Angela
Stavrakis, Georgia
Lee, Stephen J.
Schodt, David J.
Wester, Michael J.
Kumar, Dhiraj
Lidke, Keith A.
Cox, Andrea L.
Dooley, Helen M.
Nimmagadda, Sridhar
Spangler, Jamie B.
Date Issued
May 16, 2024
Type
Article
Abstract
Programmed death-ligand 1 (PD-L1) drives inhibition of antigen-specific T cell responses through engagement of its receptor programmed death-1 (PD-1) on activated T cells. Overexpression of these immune checkpoint proteins in the tumor microenvironment has motivated the design of targeted antibodies that disrupt this interaction. Despite clinical success of these antibodies, response rates remain low, necessitating novel approaches to enhance performance. Here, we report the development of antibody fusion proteins that block immune checkpoint pathways through a distinct mechanism targeting molecular trafficking. By engaging multiple receptor epitopes on PD-L1, our engineered multiparatopic antibodies induce rapid clustering, internalization, and degradation in an epitope- and topology-dependent manner. The complementary mechanisms of ligand blockade and receptor downregulation led to more durable immune cell activation and dramatically reduced PD-L1 availability in mouse tumors. Collectively, these multiparatopic antibodies offer mechanistic insight into immune checkpoint protein trafficking and how it may be manipulated to reprogram immune outcomes.
Citation
Cell Chemical Biology, 31(5), 904-919.e11, 2024